{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:24:58Z","timestamp":1787955898087,"version":"build-2784847793"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2022,7,1]]},"DOI":"10.1001\/jamacardio.2022.1166","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T15:32:48Z","timestamp":1653492768000},"page":"682","source":"Crossref","is-referenced-by-count":11,"title":["Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke"],"prefix":"10.1001","volume":"7","author":[{"given":"M. Cecilia","family":"Bahit","sequence":"first","affiliation":[{"name":"INECO Neurociencias Oro\u00f1o, Fundaci\u00f3n INECO, Rosario, Santa Fe, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit N.","family":"Vora","sequence":"additional","affiliation":[{"name":"UPMC Heart and Vascular Institute, Harrisburg, Pennsylvania"},{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuokai","family":"Li","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laine","family":"Thomas","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Terrence Donnelly Heart Center, St Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Aronson","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dedrick","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad J.","family":"Kolls","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith E.","family":"Dombrowski","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Brain Repair, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, University and Emergency Hospital, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio","family":"Berwanger","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Swiss Cardiovascular Center, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Cardiovascular Research Foundation, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"hoi220020r1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis.","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"16","key":"hoi220020r2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation.","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi220020r3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"6","key":"hoi220020r4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"issue":"6","key":"hoi220020r5","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1161\/STROKEAHA.116.012700","article-title":"Determinants and outcomes of stroke following percutaneous coronary intervention by indication.","volume":"47","author":"Myint","year":"2016","journal-title":"Stroke"},{"issue":"22","key":"hoi220020r6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013356","article-title":"Ischemic and bleeding risk after percutaneous coronary intervention in patients with prior ischemic and hemorrhagic stroke.","volume":"8","author":"Natsuaki","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"hoi220020r7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"hoi220020r8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","article-title":"An open-label, 2 \u00d7 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and\/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.","volume":"200","author":"Lopes","year":"2018","journal-title":"Am Heart J"},{"issue":"5","key":"hoi220020r9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jacc.2021.11.035","article-title":"Antithrombotic therapy in patients with atrial fibrillation after acute coronary syndromes or percutaneous intervention.","volume":"79","author":"Harskamp","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi220020r10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jth.2005.3.issue-4","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"25","key":"hoi220020r11","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI.","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi220020r12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation.","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"10206","key":"hoi220020r13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"hoi220020r14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"issue":"12","key":"hoi220020r15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"issue":"8","key":"hoi220020r16","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2792587\/jamacardiology_bahit_2022_oi_220020_1656698813.85205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T16:02:19Z","timestamp":1657728139000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2792587"}},"subtitle":["A Post Hoc Analysis From the AUGUSTUS Trial"],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2022.1166","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}